NCE-1 Intelligence & Market Opportunity

Fruzaqla

Fruquintinib

Anticancer

Capsule

Fruzaqla is a once-daily oral treatment for metastatic colorectal cancer in adults who have already tried other therapies. It inhibits VEGF receptors to slow tumor growth and improve survival.

Approval Date

08-Nov-23

NCE-1 Date

08-Nov-27

NCE Date

08-Nov-28

Commercial snapshot

Market performance & projections

Revenue ($M)

508

CAGR (%)

0.1081

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

659

2027

724

2028

739

2029

766

2030

798

2031

832

2032

865

Molecule profile

Details & specifications

Molecule

Fruquintinib

Innovator

TAKEDA PHARMACEUTICALS USA INC

Dosage Form

Capsule

Strength

1 mg & 5 mg

Therapeutic Category

Anticancer

Usage

To treat refractory, metastatic colorectal cancer

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.